Emyria Ltd
ASX:EMD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Emyria Ltd
Other Operating Expenses
Emyria Ltd
Other Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Emyria Ltd
ASX:EMD
|
Other Operating Expenses
AU$1.6m
|
CAGR 3-Years
11%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Other Operating Expenses
-AU$6.9m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Other Operating Expenses
-AU$53.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Other Operating Expenses
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Other Operating Expenses
AU$9.5m
|
CAGR 3-Years
14%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vita Life Sciences Ltd
ASX:VLS
|
Other Operating Expenses
-AU$571k
|
CAGR 3-Years
-4%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-10%
|
|
Emyria Ltd
Glance View
Emyria Ltd. is a healthcare technology and services company. The firm provides care for its patients through its clinics gathering real-world-evidence (RWE) insights in relation to therapies, such as cannabinoid-based medicines and drug development. Its evidence-based drug development program (EMD-003) is focused on mental health and EMD-004 is focused on irritable bowel syndrome (IBS). The Company’s subsidiaries include Emyria Clinical Network Pty Ltd and Openly Care Inc.
See Also
What is Emyria Ltd's Other Operating Expenses?
Other Operating Expenses
1.6m
AUD
Based on the financial report for Jun 30, 2025, Emyria Ltd's Other Operating Expenses amounts to 1.6m AUD.
What is Emyria Ltd's Other Operating Expenses growth rate?
Other Operating Expenses CAGR 5Y
28%
Over the last year, the Other Operating Expenses growth was -37%. The average annual Other Operating Expenses growth rates for Emyria Ltd have been 11% over the past three years , 28% over the past five years .
